Abstract
OBJECTIVE. The aim of this study was to investigate the association between perfusion parameters on MRI performed before treatment and survival outcome (disease-free survival [DFS], disease-specific survival [DSS]) in patients with triple-negative breast cancer (TNBC). MATERIALS AND METHODS. Sixty-one patients (median age, 50 years; age range, 27-77 years) with TNBC (tumor size on MRI: Median, 25.5 mm; range, 11.0-142.0 mm) were included. We analyzed clinical and pathologic variables and MRI parameters. Cox proportional hazards models were used to determine associations with survival outcome. RESULTS. The median follow-up time was 46.1 months (range, 13.9-58.4 months). Eleven of 61 (18.0%) patients had events (i.e., local, regional, or distant recurrence or contralateral breast cancer) and seven (11.5%) died of breast cancer. Among the pretreatment variables, a larger tumor size on MR images (hazard ratio [HR] = 1.024, p = 0.003) was associated with worse DFS at univariate analysis. In multivariate pretreatment models for DSS, a higher fractional volume of extravascular extracellular space per unit volume of tissue (ve) value (HR = 1.658, p = 0.038), higher peak enhancement (HR = 1.843, p = 0.018), and a larger tumor size on MR images (HR = 1.060, p = 0.001) were associated with worse DSS. In multivariate posttreatment models, a larger pathologic tumor size (HR for DFS, 1.074 [p = 0.005]; HR for DSS, 1.050 [p = 0.042]) and metastasis in surgically resected axillary lymph nodes (HR for DFS, 5.789 [p = 0.017]; HR for DSS, 23.717 [p = 0.005]) were associated with worse survival outcome. CONCLUSION. A higher ve value, higher peak enhancement, and larger tumor size of the primary tumor on pretreatment MRI were independent predictors of worse DSS in patients with TNBC.
| Original language | English |
|---|---|
| Pages (from-to) | 687-694 |
| Number of pages | 8 |
| Journal | American Journal of Roentgenology |
| Volume | 208 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2017 Mar |
Fingerprint
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
Cite this
}
Perfusion parameters on breast dynamic contrast-enhanced MRI are associated with disease-specific survival in patients with triple-negative breast cancer. / Park, Vivian Youngjean; Kim, Eun Kyung; Kim, Min Jung; Yoon, Jung Hyun; Moon, Hee Jung.
In: American Journal of Roentgenology, Vol. 208, No. 3, 03.2017, p. 687-694.Research output: Contribution to journal › Article
TY - JOUR
T1 - Perfusion parameters on breast dynamic contrast-enhanced MRI are associated with disease-specific survival in patients with triple-negative breast cancer
AU - Park, Vivian Youngjean
AU - Kim, Eun Kyung
AU - Kim, Min Jung
AU - Yoon, Jung Hyun
AU - Moon, Hee Jung
PY - 2017/3
Y1 - 2017/3
N2 - OBJECTIVE. The aim of this study was to investigate the association between perfusion parameters on MRI performed before treatment and survival outcome (disease-free survival [DFS], disease-specific survival [DSS]) in patients with triple-negative breast cancer (TNBC). MATERIALS AND METHODS. Sixty-one patients (median age, 50 years; age range, 27-77 years) with TNBC (tumor size on MRI: Median, 25.5 mm; range, 11.0-142.0 mm) were included. We analyzed clinical and pathologic variables and MRI parameters. Cox proportional hazards models were used to determine associations with survival outcome. RESULTS. The median follow-up time was 46.1 months (range, 13.9-58.4 months). Eleven of 61 (18.0%) patients had events (i.e., local, regional, or distant recurrence or contralateral breast cancer) and seven (11.5%) died of breast cancer. Among the pretreatment variables, a larger tumor size on MR images (hazard ratio [HR] = 1.024, p = 0.003) was associated with worse DFS at univariate analysis. In multivariate pretreatment models for DSS, a higher fractional volume of extravascular extracellular space per unit volume of tissue (ve) value (HR = 1.658, p = 0.038), higher peak enhancement (HR = 1.843, p = 0.018), and a larger tumor size on MR images (HR = 1.060, p = 0.001) were associated with worse DSS. In multivariate posttreatment models, a larger pathologic tumor size (HR for DFS, 1.074 [p = 0.005]; HR for DSS, 1.050 [p = 0.042]) and metastasis in surgically resected axillary lymph nodes (HR for DFS, 5.789 [p = 0.017]; HR for DSS, 23.717 [p = 0.005]) were associated with worse survival outcome. CONCLUSION. A higher ve value, higher peak enhancement, and larger tumor size of the primary tumor on pretreatment MRI were independent predictors of worse DSS in patients with TNBC.
AB - OBJECTIVE. The aim of this study was to investigate the association between perfusion parameters on MRI performed before treatment and survival outcome (disease-free survival [DFS], disease-specific survival [DSS]) in patients with triple-negative breast cancer (TNBC). MATERIALS AND METHODS. Sixty-one patients (median age, 50 years; age range, 27-77 years) with TNBC (tumor size on MRI: Median, 25.5 mm; range, 11.0-142.0 mm) were included. We analyzed clinical and pathologic variables and MRI parameters. Cox proportional hazards models were used to determine associations with survival outcome. RESULTS. The median follow-up time was 46.1 months (range, 13.9-58.4 months). Eleven of 61 (18.0%) patients had events (i.e., local, regional, or distant recurrence or contralateral breast cancer) and seven (11.5%) died of breast cancer. Among the pretreatment variables, a larger tumor size on MR images (hazard ratio [HR] = 1.024, p = 0.003) was associated with worse DFS at univariate analysis. In multivariate pretreatment models for DSS, a higher fractional volume of extravascular extracellular space per unit volume of tissue (ve) value (HR = 1.658, p = 0.038), higher peak enhancement (HR = 1.843, p = 0.018), and a larger tumor size on MR images (HR = 1.060, p = 0.001) were associated with worse DSS. In multivariate posttreatment models, a larger pathologic tumor size (HR for DFS, 1.074 [p = 0.005]; HR for DSS, 1.050 [p = 0.042]) and metastasis in surgically resected axillary lymph nodes (HR for DFS, 5.789 [p = 0.017]; HR for DSS, 23.717 [p = 0.005]) were associated with worse survival outcome. CONCLUSION. A higher ve value, higher peak enhancement, and larger tumor size of the primary tumor on pretreatment MRI were independent predictors of worse DSS in patients with TNBC.
UR - http://www.scopus.com/inward/record.url?scp=85013662074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013662074&partnerID=8YFLogxK
U2 - 10.2214/AJR.16.16476
DO - 10.2214/AJR.16.16476
M3 - Article
C2 - 28004976
AN - SCOPUS:85013662074
VL - 208
SP - 687
EP - 694
JO - American Journal of Roentgenology
JF - American Journal of Roentgenology
SN - 0361-803X
IS - 3
ER -